Scarica l'app Stockscreener
31.65
1.65%
-0.53
Dopo l'orario di chiusura:
31.75
0.10
+0.32%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$32.18
Aprire:
$32.26
Volume 24 ore:
2.41M
Relative Volume:
1.94
Capitalizzazione di mercato:
$2.49B
Reddito:
$866.00K
Utile/perdita netta:
$-283.65M
Rapporto P/E:
-7.4174
EPS:
-4.267
Flusso di cassa netto:
$-226.25M
1 W Prestazione:
+1.77%
1M Prestazione:
-19.83%
6M Prestazione:
+1.90%
1 anno Prestazione:
+22.44%
Intervallo 1D:
$30.98
$32.54
Intervallo di 1 settimana:
$30.38
$32.76
Portata 52W:
$22.10
$45.14
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Nome
Celldex Therapeutics Inc
Settore
Industria
Telefono
908-200-7500
Indirizzo
53 FRONTAGE ROAD, HAMPTON
Compare CLDX vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
31.65 | 2.44B | 866.00K | -283.65M | -226.25M | -4.267 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-20 | Aggiornamento | Barclays | Underweight → Overweight |
| 2026-03-23 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-10-13 | Iniziato | Barclays | Underweight |
| 2025-04-28 | Iniziato | Canaccord Genuity | Buy |
| 2025-03-20 | Iniziato | Morgan Stanley | Overweight |
| 2025-02-13 | Iniziato | UBS | Buy |
| 2024-10-07 | Iniziato | Citigroup | Buy |
| 2024-09-30 | Iniziato | Goldman | Neutral |
| 2024-09-27 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | Iniziato | Stifel | Buy |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2023-12-20 | Iniziato | TD Cowen | Outperform |
| 2023-11-10 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | Iniziato | Wells Fargo | Underweight |
| 2021-09-17 | Iniziato | Jefferies | Buy |
| 2021-09-10 | Iniziato | SVB Leerink | Outperform |
| 2021-07-22 | Iniziato | Guggenheim | Buy |
| 2020-02-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-08-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-07 | Iniziato | Aegis Capital | Buy |
| 2016-03-08 | Downgrade | Jefferies | Buy → Hold |
| 2016-03-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2016-03-07 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2016-03-01 | Iniziato | H.C. Wainwright | Buy |
| 2015-08-11 | Reiterato | Brean Capital | Buy |
| 2015-08-11 | Reiterato | Oppenheimer | Outperform |
| 2015-08-11 | Reiterato | ROTH Capital | Buy |
| 2015-06-02 | Reiterato | WBB Securities | Strong Buy |
| 2014-11-17 | Reiterato | ROTH Capital | Buy |
| 2014-03-04 | Reiterato | Oppenheimer | Outperform |
| 2013-07-08 | Reiterato | Cantor Fitzgerald | Buy |
| 2013-03-08 | Reiterato | Cantor Fitzgerald | Buy |
| 2013-02-26 | Reiterato | Oppenheimer | Outperform |
| 2013-01-10 | Reiterato | Cantor Fitzgerald | Buy |
| 2012-10-02 | Reiterato | Oppenheimer | Outperform |
| 2012-09-14 | Reiterato | Cantor Fitzgerald | Buy |
Mostra tutto
Celldex Therapeutics Inc Borsa (CLDX) Ultime notizie
The week in pharma: action, reaction and insight – week to September 25, 2026 - The Pharma Letter
Celldex Therapeutics, Inc. (CLDX) Stock Price, News, Quote & History - Yahoo Finance
Yaron Werber: Celldex's Urticaria Drug Won't Carry a Black Box; Amgen Maps a $25 Billion Sjogren's Market - finance.biggo.com
Is Celldex Therapeutics, Inc. (CLDX) the Healthcare Stocks Stock Everyone's About to Talk About? - Kalkine Media
What Do Positive Barzolvolimab Results Mean for Celldex (NASDAQ:CLDX)? - Kalkine Media
Celldex shares slip 15% as safety concerns cloud skin drug trial win - The Economic Times
Celldex Therapeutics Leads Guggenheim’s Biotechnology Rankings By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $64 - Moomoo
Celldex's price target jumps to $88 after positive Phase III trial for chronic urticaria drug. - Pluang
Leerink Partners maintains Outperform rating on Celldex Therapeutics, $88 price target - TradingView
Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success? - Yahoo Finance
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Yahoo Finance
Morgan Stanley raises Celldex Therapeutics price target on urticaria drug progress - Investing.com Canada
Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous UrticariaSlideshow (NASDAQ:CLDX) 2026-09-22 - Seeking Alpha
Celldex Therapeutics upgraded to Buy after posi... - Pluang
Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results - Benzinga
Celldex's Barzolvolimab Hits Mark in Two Phase 3 Trials for Chronic Hives - finance.biggo.com
CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’ - tradingview.com
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease - Benzinga
Celldex Therapeutics Shares Fall After Phase 3 Readout Despite Positive Trial Results - Quiver Quantitative
4 Biotech Stocks With Key Clinical Readouts Expected This Fall - theglobeandmail.com
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses - Yahoo Finance
Celldex sinks as safety concerns cloud immune drug results - BioPharma Dive
Celldex's barzolvolimab hits primary and secondary endpoints in twin Phase III CSU trials - thepharmaletter.com
Celldex Shares Rise 8% as Barzolvolimab Meets Primary Endpoints in Two Phase 3 Trials - Yahoo Finance
Celldex stock falls after hives trial data (CLDX:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Celldex reports positive phase 3 trial results for CSU drug By Investing.com - Investing.com Canada
Celldex reports strong Phase 3 data in urticaria - TipRanks
Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria Trials - marketscreener.com
Celldex stock rises after positive phase 3 trial results By Investing.com - Investing.com Canada
Celldex announces Phase 3 barzolvolimab trials meet primary and all key secondary endpoints - TradingView
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 - GlobeNewswire
Celldex Therapeutics stock gains as analysts target USD 56.42 - AD HOC NEWS
Celldex Reports Positive Phase 3 Results for Barzolvolimab - Intellectia AI
Asthma Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 80+ Leading Players Wheeling the Therapeutics Landscape - Barchart.com
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) - Eastern Progress
TLX Stock Price and Chart — NASDAQ:TLX - TradingView
Celldex Therapeutics stock gains as analysts lift expectations - AD HOC NEWS
Celldex at Cantor conference: barzolvolimab data loom By Investing.com - Investing.com Canada
Celldex to Present at Upcoming Investor Conference - The Manila Times
Celldex's investor talk will stream online Sept. 10 - Stock Titan
Celldex (CLDX) Q2 2026 Earnings: The Available Earnings Metric Delivers a Beat in Latest Trading; Post-Earnings: The Stock Records a 1.60% Increase at the CloseGuidance Downgrade Alert - dars.gov.et
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cue Biopharma, Inc. (NASDAQ: CUE) - PR Newswire
Celldex Therapeutics, Inc. Revenue Breakdown – NASDAQ:CLDX - TradingView
Celldex (CLDX) Quarterly Results: Profit Per Share Clears Its Benchmark on the Day; Market Reaction - vinanet.vn
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Celldex (CLDX) Momentum: Adds 0.32% to Close at $41.92 in the Current Update; Range Check - vinanet.vn
Celldex Therapeutics, Inc. $CLDX Shares Acquired by Bank of America Corp DE - MarketBeat
Celldex Therapeutics (CLDX) Slips 1.55% to $41.95 as Clinical-Stage Biotech ConsolidatesMomentum Surge Alerts - vinanet.vn
Kynam Capital (CLDX) group discloses 6.78% Celldex Therapeutics ownership stake - Stock Titan
Celldex Therapeutics Inc Azioni (CLDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Celldex Therapeutics Inc Azioni (CLDX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| PEPIN RONALD | SR. VP & CBO |
Dec 15 '25 |
Option Exercise |
5.47 |
19,333 |
105,714 |
20,097 |
| Jimenez Freddy A. | SVP & GENERAL COUNSEL |
Dec 04 '25 |
Sale |
29.09 |
4,166 |
121,210 |
30,796 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):